Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavorixafor in WHIM Syndrome
NCT03005327Phase 2Completed
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Dec 2016
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of mavorixafor in WHIM syndrome (WHIM), sponsored by X4 Pharmaceuticals, Inc. Primary endpoints: Area Under the Plasma Concentration-time Curve for Absolute Neutrophil Count at Week 21, Average Per-Participant Value of the AUCANC at Week 21 and 3 more. Started Dec 2016; status: completed.
02
Drugs
mavorixafor
03
Conditions
WHIM syndrome (WHIM)
Beyond the preview
Go deeper on NCT03005327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03005327.